Assessing the Clinical Improvement in Patients with COVID-19 using Lopinavir-Ritonavir: A Systematic Review

被引:0
作者
Magadmi, Rania M. [1 ]
机构
[1] King Abdulaziz Univ, Dept Pharmacol, Fac Med, Jeddah, Saudi Arabia
关键词
Antiviral; Clinical Improvement; COVID-19; Lopinavir-ritonavir; RESPIRATORY SYNDROME CORONAVIRUS; TRIPLE COMBINATION; DISEASE; 2019; LOPINAVIR/RITONAVIR; INHIBITORS; RIBAVIRIN;
D O I
10.9734/JPRI/2021/v33i44A32637
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims: Globally the focus is towards finding an effective treatment for COVID-19 patients in order to suppress the spread of this pandemic disease. An antiviral combination of lopinavir-ritonavir is considered to be effective in treating COVID-19 patients. Therefore, the present study aims to assess the clinical improvements of lopinavir-ritonavir in COVID-19 patients. Study Design: a systematic review study was conducted and articles published since December 2019 were included. The statistical analysis of quantitative data was performed using Review Manager (RevMan) to generate forest plots. Results: The study showed that there was no significant difference in COVID-19 patients treated with lopinavir-ritonavir or in combination with anti-viral therapy or other conventional methods. Conclusion: the use of lopinavir-ritonavir resulted in greater adverse consequences among COVID-19 patients. It further recommends conducting meta-analysis studies with a greater number of studies to highlight the clinical improvement associated with the use of Lopinavir-ritonavir.
引用
收藏
页码:448 / 459
页数:12
相关论文
共 34 条
  • [31] Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
    Yan, Dan
    Liu, Xiao-Yan
    Zhu, Ya-nan
    Huang, Li
    Dan, Bi-tang
    Zhang, Guo-jun
    Gao, Yong-hua
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2020, 56 (01)
  • [32] Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
  • [33] The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients
    Yuan, Jing
    Zou, Rougrong
    Zeng, Lijiao
    Kou, Shanglong
    Lan, Jianfeng
    Li, Xiaohe
    Liang, Yanhua
    Ding, Xiaoyan
    Tan, Guoyu
    Tang, Shenghong
    Liu, Lei
    Liu, Yingxia
    Pan, Yanchao
    Wang, Zhaoqin
    [J]. INFLAMMATION RESEARCH, 2020, 69 (06) : 599 - 606
  • [34] Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
    Zhu, Zhen
    Lu, Zhaohui
    Xu, Tianmin
    Chen, Cong
    Yang, Gang
    Zha, Tao
    Lu, Jianchun
    Xue, Yuan
    [J]. JOURNAL OF INFECTION, 2020, 81 (01) : E21 - E23